The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study by unknown
Solanki et al. Radiation Oncology 2012, 7:216
http://www.ro-journal.com/content/7/1/216RESEARCH Open AccessThe utility of FDG-PET for assessing outcomes in
oligometastatic cancer patients treated with
stereotactic body radiotherapy: a cohort study
Abhishek A Solanki1, Ralph R Weichselbaum1,2,3, Daniel Appelbaum4, Karl Farrey1, Kamil M Yenice1,
Steven J Chmura1,2,3 and Joseph K Salama5*Abstract
Background: Studies suggest that patients with metastases limited in number and destination organ benefit from
metastasis-directed therapy. Stereotactic body radiotherapy (SBRT) is commonly used for metastasis directed
therapy in this group. However, the characterization of PET response following SBRT is unknown in this population.
We analyzed our cohort of patients to describe the PET response following SBRT.
Methods: Patients enrolled on a prospective dose escalation trial of SBRT to all known sites of metastatic disease
were reviewed to select patients with pre- and post-therapy PET scans. Response to SBRT was characterized on PET
imaging based on standard PET response criteria and compared to CT based RECIST criteria for each treated lesion.
Results: 31 patients had PET and CT data available before and after treatment for analysis in this study. In total, 58
lesions were treated (19 lung, 11 osseous, 11 nodal, 9 liver, 6 adrenal and 2 soft tissue metastases). Median
follow-up was 14 months (range: 3–41). Median time to first post-therapy PET was 1.2 months (range; 0.5-4.1).
On initial post-therapy PET evaluation, 96% (56/58) of treated metastases responded to therapy. 60% (35/58) had a
complete response (CR) on PET and 36% (21/58) had a partial response (PR). Of 22 patients with stable disease (SD)
on initial CT scan, 13 had CR on PET, 8 had PR, and one had SD. Of 21 metastases with PET PR, 38% became CR,
52% remained PR, and 10% had progressive disease on follow-up PET. 10/35 lesions (29%) with an initial PET CR
progressed on follow-up PET scan with median time to progression of 4.11 months (range: 2.75-9.56). Higher
radiation dose correlated with long-term PET response.
Conclusions: PET response to SBRT enables characterization of metastatic response in tumors non-measurable
by CT. Increasing radiation dose is associated with prolonged complete response on PET.
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Metastases are the most common cause of cancer
related mortality. The standard treatment for most
metastatic cancer patients is usually chemotherapy
or hormonal deprivation. Although chemotherapy has
improved median survival duration in patients with
metastatic cancer, response rates are low and chemo-
therapy is rarely curative, except in cases of hematologic
malignancies and germ cell tumors [1-6]. Previously,* Correspondence: joseph.salama@duke.edu
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reproduction in any medium, provided the orit has been proposed that within the spectrum of meta-
static disease, a group of patients exists with metastases
limited in number and location (i.e. oligometastatic
patients), who may benefit from metastasis-directed
therapy [7]. This hypothetical disease state is supported
by long-term survival rates of 20-50% in patients under-
going limited pulmonary and hepatic metastasectomy
[8,9]. Recent technical developments in radiotherapy
planning and delivery have allowed metastatic patients
who are not medically fit for surgery, or those who are
technically unresectable, to be treated with a few frac-
tions of high doses of radiation to each lesion. Termed
stereotactic body radiotherapy (SBRT), these techniquesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with limited metastases disease-free [10,11] .
Response assessment following SBRT is typically per-
formed via computed tomography (CT) scans with each
individual lesion measured using RECIST criteria [12].
However, due to architectural changes of normal tissues
surrounding treated metastases, particularly post-SBRT
scarring, RECIST criteria are often difficult to use [13].
Furthermore, osseous metastases are not measureable by
standard RECIST criteria, complicating assessment of
treatment response in these regions commonly involved
with oligometastases.
2-[18F]-fluoro-2-deoxy-D-glucose positron emission
tomography (PET) imaging is a common metabolic
imaging technique used to stage many cancer patients as
well as assess outcomes following treatment. PET is par-
ticularly helpful in cases where anatomy has been
altered, such as due to radiotherapy fibrosis or necrosis,
where magnetic resonance imaging (MRI) and computed
tomography (CT) may not be able to differentiate malig-
nant pathology from post treatment changes [14,15]. To
our knowledge, there are no data on the use of PET
for assessing SBRT response in patients with oligometa-
static disease. Therefore, we evaluated the utility of PET
as an indicator of treatment response in oligometastatic
patients undergoing SBRT.
Methods
Patients included in this analysis were selected from par-
ticipants in an IRB approved dose escalation study asses-
sing the role of SBRT to all known sites of metastases in
oligometastatic patients. From these patients, we identi-
fied those with PET imaging both prior to and after
radiotherapy to form our study population.
We have previously reported trial methods and treat-
ment outcomes [10]. Briefly, patients were eligible if
they had pathologically confirmed stage IV metastatic
cancer, were ≥ 18 years of age, had life expectancy of
> 3 months, with metastases amenable to radiation ther-
apy as seen on standard imaging (CT, MRI, PET, or bone
scan). Patients were excluded if they had coexisting ma-
lignancies, uncontrolled medical comorbidity, active in-
fectious processes, or exudative, bloody, or cytologically
malignant effusions. Concurrent systemic chemotherapy
was not allowed during radiotherapy. Each metastatic le-
sion was grouped into one of the following five disease
sites: liver, lung, abdominal, head and neck, or extremity.
Radiotherapy
Prior to SBRT, all patients were simulated in custom-
made immobilization devices. Typically, patients under-
went contrast-enhanced CT-based radiotherapy treatment
planning, including four-dimensional CT scans as needed
to allow visualization and assessment of internal organmotion. For tumors with motion, an internal target vol-
ume (ITV) was generated based on maximal intensity
projection images from either the entire respiratory cycle
or end-expiratory phase, as appropriate based on tumor
motion. Otherwise, the gross tumor volume (GTV) was
contoured on free breathing scans. Diagnostic images
(MRI, PET, triple-phase CT, etc.) were anatomically regis-
tered to the planning CT scans to assist with target delin-
eation. GTVs were delineated on each CT slice, typically
with a 5–7 mm expansion, for organ motion and set-up
uncertainty only, to create the PTV. For lesions within
the bone, a larger CTV expansion was used to encompass
microscopic bony involvement.
3D conformal techniques, including both coplanar and
non-coplanar beam arrangements were used for radi-
ation planning. Radiotherapy was typically prescribed to
the 85% isodose line. The starting dose for all sites was
24 Gy in 3 fractions. A standard 3 + 3 dose escalation
schema was used with SBRT dose per treatment increas-
ing in 2 Gray (Gy) increments to each lesion. Each lesion
received the same dose throughout all three treatments,
but different lesions within the same patient could re-
ceive different doses. The time between consecutive frac-
tions was a minimum of 48 hours and a maximum of
192 hours. At the discretion of the treating radiation on-
cologist, alternative dosing schedules could be used for
larger metastases not amenable to three fraction treat-
ment as this had been previously shown to be safe and
effective for metastatic patients [16].
Regardless of dose and fractionation used, prior to
each treatment, image-guidance with gated kilovoltage
(KV) orthogonal images and/or non-gated KV cone
beam CT scans were acquired and appropriate adjust-
ments made by the attending physician. With bony anat-
omy correlated, each metastasis was verified to fall
within the planning target volume. If this did not occur,
patients were replanned.
Imaging schedule
Baseline CT scans of the chest, abdomen, and pelvis
along with PET scans were obtained no more than
1 month prior to the start of treatment. Patients
returned to clinic every 2 weeks for the first month fol-
lowing treatment, then monthly for the first 3 months,
followed by every 3 months thereafter. Imaging was per-
formed one month following the completion of SBRT
and then prior to each additional follow-up visit, at
which time a complete history and physical was also per-
formed. All images were evaluated by radiologists at the
University of Chicago Medical Center.
Response assessment
Each metastatic lesion was independently considered a
target lesion and assessed for response to its localized
Table 1 Patient and Tumor Characteristics.
Characteristic N %





Non-small Cell Lung 9 16%
Sarcoma 5 9%
Breast 4 7%
Head and Neck 4 7%
Colon 4 7%
Small Cell Lung 3 5%




Lymph Node 11 19%
Osseous 11 19%
Liver 9 16%
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target lesions were followed on subsequent imaging for
analysis of patterns of progression.
CT response was defined by RECIST criteria [12]. Based
on these criteria, a complete response (CR) was total reso-
lution of tumor, partial response (PR) was ≥ 30% decrease in
the longest diameter of a lesion, stable disease (SD) was be-
tween a < 30% decrease and a < 20% increase in the longest
diameter, and progressive disease (PD) was a ≥ 20% increase
in the lesion.
PET scan interpretation was performed by a nuclear
medicine radiologist. Positive PET uptake was deter-
mined by visual analysis and/or maximum standardized
uptake value (SUV) > 2.5. Areas of no uptake or diffuse
poorly defined low uptake were considered to be non-
malignant and negative. A PET CR was defined as
complete resolution of uptake or normalization to sur-
rounding tissue uptake. PET PR was a ≥ 30% decrease in
maximum SUV or partial decrease in uptake by visual
assessment. PET SD was no change in uptake by visual
assessment or < 30% decrease or < 20% increase in max-
imum SUV. Progressive disease was defined as increased
uptake by visual assessment of ≥ 20% increase in SUV.Adrenal 6 10%
Soft tissue 2 3%
Dose
24 Gray 19 33%
30 Gray 20 35%
36 Gray 8 14%
42 Gray 9 16%
50 Gray 2 3%Results
This analysis was performed after the first 50 patients par-
ticipating in the dose escalation trial had been enrolled. Of
these, 31 patients had PET and CT data available before
and after treatment for analysis in this study. Patient and
tumor characteristics are presented in Table 1. Median
follow-up was 14 months (range: 3–41 months). Median
time from cancer diagnosis to the development of metas-
tastic disease was 11.1 months (range: 0–299 months).
Median time from development of metastatic disease to
SBRT was 6.9 months (range: 0–59.1 months). Median
number of chemotherapy regimens received prior to SBRT
was 1 (range: 0–4).
The majority of patients were women (52%). The most
common primary histology treated was non-small cell
lung cancer (9 patients), followed by sarcoma (5 patients),
breast (4 patients), colon (4 patients), and head and neck
cancer (4 patients). In total 58 metastatic lesions were
treated, including 19 lung, 11 osseous, 11 nodal, 9 liver,
6 adrenal and 2 soft tissue. Treatment dose was selected
per protocol and listed in Table 1. Two patients were trea-
ted with 50 Gy in 10 daily fractions of 5 Gy.
Following treatment, the median time to the first post-
therapy PET was 1.2 months (range: 0.5-4.1). All patients
had one post-therapy PET, 24 of 31 (77%) had two post ther-
apy PET scans and 9 of 31 (29%) had three post-therapy
PET scans. The median time to the second PET scan was 4.4
months (range: 1.4-26.8 months) and the median time to
third PET scan was 7.1 months (range: 6.4-20.4 months).Initial response to therapy
On initial post-therapy PET evaluation, 96% (56 of 58)
of treated metastases responded to therapy. This
included 60% (35 of 58) with a PET CR and 36% (21 of
58) with a PET PR. Forty-eight of 58 treated tumors
were evaluable for CT response. The other ten lesions
were non-measurable by RECIST criteria. On initial
post-therapy CT evaluation, 52% (25 of 48) had a re-
sponse, with 19% (9 of 48) being a CR and 33% (16 of
48) a PR. Initial CT response to therapy was generally
in agreement with PET response. Eight of nine meta-
stases with an initial CR on CT also had an initial
PET CR. One patient with an adrenal metastasis had
resolution of his adrenal metastasis on CT scan but per-
sistent activity (SD) on PET scan. Of the ten patients
with non-measureable disease on initial CT scan, all had
a PET response with 5 having a PET CR and 5 with
a PET PR. Of the 22 patients with SD on initial CT
scan, 13 had a PET CR, 8 had a PET PR, and one had





CR PR SD PD Total
CR 22 (63%) 1 (3%) 0 12 (35%) 35
PR 8 (38%) 11 (52%) 1 (5%) 1 (5%) 21
SD 1 (100%) 0 0 0 1
PD 0 0 0 1 (100%) 1
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initial response in patients with stable disease on initial
CT scan.
Patients with adrenal metastases and nodal metastases
were more likely to have an initial PET CR than other
metastatic sites. Eighty-three percent (5 of 6) of adrenal
lesions and 82% (9 of 11) of nodal lesions had an initial
PET CR. In comparison, 53% (9 of 19) of pulmonary
metastases, 56% (5 of 9) of hepatic metastases, and 55%
(6 of 11) of osseous metastases had an initial PET CR.
Increasing radiation dose was not associated with in-
creasing initial PET CR as shown in Table 2. Forty-eight
percent of patients treated at 24 Gy, 60% treated at
30 Gy, 50% treated at 36 Gy, and 55% treated at 42 Gy
had an initial PET CR. All patients treated with a mini-
mum of 36 Gy had an initial PET response. No patient
treated with 50 Gy in 5 Gy fractions had a PET CR, but
only two patients were treated with this regimen.Utility of continued PET surveillance
Continued PET follow-up was useful. Table 3 depicts the
initial and cumulative PET response of each treated
lesion. Of the 21 metastases with an initial PET PR,
8 (38%) became a PET CR, 11 (52%) remained a PET
PR, and 2 (10%) demonstrated PD on PET scan. Thus,
over half of patients with a PET PR maintained the PR
and over one third improved to a PET CR. Similarly, 12
of 35 lesions (35%) with an initial PET CR progressed on
follow-up PET scan. One lesion with an initial SD on
PET, converted to a CR with further PET imaging. The
median time to conversion from CR to PD was 4.11
months (range: 2.75-9.56) and corresponded with the
second PET scan.
Contrary to initial PET response, long-term PET
response correlated with increasing radiotherapy dose.
All lesions receiving >30 Gy had responded on the initialTable 2 Comparison of PET and CT response by dose cohort.
Dose I
CR PR
CT PET CT PET
n (%) n (%) n (%) n (%)
24 Gy (n=19) 4 (24%) 14 (74%) 8 (47%) 4 (21%)
30 Gy (n=20) 3 (21%) 12 (60%) 3 (21%) 7 (35%)
36 Gy (n=8) 1 (14%) 4 (50%) 1 (14%) 4 (50%)
42 Gy (n=9) 1 (14%) 5 (55%) 2 (29%) 4 (44%)
50 Gy (n=2) 0 0 2 (100%) 2 (100%)





SD stable disease.post-therapy PET. Long term metabolic response was
maintained with higher radiotherapy doses. Of patients
with an initial PET CR, 50% (7 of 14) progressed meta-
bolically at the 24 Gy level, compared to 16.6% (2 of 12)
at 30 Gy, 25% (1 of 4) at 36 Gy, and 0% (0 of 5) at
42 Gy.
Long-term PET response also differed based on metas-
tasis location. Of the 19 pulmonary metastases, 9 (47%)
had a long-term PET CR and 6 (32%) had a PET PR.
Seven of eleven (63%) lymph node metastases had long
term PET CR. Six of nine hepatic metastases remained
in metabolic response long-term as well. All osseous
metastases had either a CR or PR on initial PET, and
none progressed by metabolic imaging at last follow-up.
Certain primary histologies were associated with
increased risk of progression on PET. Three of four
(75%) metastatic lesions from small cell lung cancer pro-
gressed metabolically. Additionally, four of seven (57%)
metastatic colon cancer lesions had metabolic progres-
sion. All breast (5 of 5), sarcoma (7 of 7), and four of five
head and neck cancer metastases remained in metabolic
response at last follow-up.nitial Response
SD PD Non-measurable
CT PET CT PET CT
n (%) n (%) n (%) n (%) n (%)
4 (24%) 0 1 (6%) 1 (5%) 2 (11%)
8 (57%) 1 (5%) 0 0 6 (30%)
5 (71%) 0 0 0 1 (13%)
5 (71%) 0 0 0 1 (13%)
0 0 0 0 0
22 (46%) 1 (2%) 1 (2%) 1 (2%) 10 (17%)
Solanki et al. Radiation Oncology 2012, 7:216 Page 5 of 8
http://www.ro-journal.com/content/7/1/216Follow-up PET imaging was also useful in the detec-
tion of further metastatic progression outside of treated
sites. Distant progression was detected on PET scans in
17 of 31 patients (55%). PET was able to identify radio-
graphically occult distant metastases in 5 of 31(16%).
Median time to progression after SBRT was 4.5 months
(range: <1 month-35.3 months). At 6 months, 45% of
patients were free of progression, while at one year,
39% were free of disease. There was no difference in the
pattern of progression (treated metastasis vs. new meta-
static site) based on histology (p=0.06), or number of
metastases at progression (p=0.87). There were two few
numbers of some histologies to compare the time to
progression. 8 patients had progression in treated metas-
tases as the first site of progression while 15 had pro-
gression in new metastases and 2 had both progression
in treated and new metastatic sites. 52 patients had 1 site
of progression, 2 patients had 2 sites, 5 patients had
3 sites, and one each had 5 and 6 sites. Median survival
was 31.7 months (range: 5.9 months-55.1 months) in
our cohort of patients.Discussion
Clinical decision making for metastatic patients under-
going treatment hinges on the clinician’s ability to accur-
ately assess the initial therapy response, as well as the
duration of response. CT and MRI are routinely used to
evaluate response to therapy, with RECIST criteria being
used to assess response for patients on study and similar
criteria used for off study patients. However, as used in
routine clinical practice, these technologies and meas-
urement standards have limitations. Postsurgical and
postradiotherapy changes alter fascial planes and create
fibrosis and necrosis of both malignant tissue as well as
surrounding normal tissue, often making it difficult to
differentiate between malignant and non-malignant tis-
sues in surveillance CT and MRI imaging [14,15,17,18].
This is especially the case when the size of tumor does
not change even though pathologically the tissue is no
longer malignant.
PET technology is reliant upon the altered metabolic
biology of malignant cells compared to normal cells [19].
2-[18F]-fluoro-2-deoxy-D-glucose is the most frequently
utilized radiotracer in clinical practice. As availability
and technology improve, PET is increasingly being
used in diagnosis, staging, radiotherapy planning, early
response assessment, and restaging after completion of
therapy for several malignancies [19]. In the detection
of recurrent head and neck tumors, PET has been
shown to have a sensitivity and specificity approaching
90-100% [20-22], and in primary lung cancer, PET is in-
creasingly used to differentiate tumor from atelectasis
and consolidation.In our study, we found that FDG-PET appeared to be
a useful adjunct for response assessment for patients
with oligometastatic disease treated with SBRT. Not
only did most patients with a CT response have a PET
response, but patients who were not evaluable with
CT were able to be assessed with PET scan effectively.
Furthermore, many of the patients with partial response
on PET proceeded to have a complete PET response with
further follow-up. This can be seen in Figure 1, which
depicts the sequential PET imaging from a patient in
our study.
In our patient population, PET was helpful in assessing
a response in patients with stable disease by anatomic
evaluation on CT. This has significant implications on
clinical decision making. The concern for treatment
resistant disease makes it crucial for the clinician to rely
on imaging to monitor disease response. However,
disease may not morphologically change on CT scan. In
this situation, PET allows for an understanding of tumor
physiology, and hence a decrease in metabolic uptake
(PR or CR) would indicate decreased tumor activity and
possible response to treatment. In the setting of a stable
CT examination, this could decrease unnecessary or un-
timely changes of treatment for suspected resistance to
treatment. A stable CT scan can mean a number of
things in this situation. The patient could have fibrosis
or necrosis secondary to treatment, or conditions such
as atelectasis in the lung [14, 22, 23]. On CT it could be
difficult to identify viable tumor tissue compared to
these post-treatment changes, but on PET it would be
easier to distinguish tumor from normal tissue. PET
may have a role in assessing response after SBRT in pri-
mary and metastatic lung tumors [24, 25, 26]. PET ima-
ging’s strength is in this ability to differentiate for both
planning purposes as well as long term analysis of
patterns of progression.
Interestingly, patients in our study with osseous me-
tastases had very encouraging early and late response to
SBRT. As osseous metastases cannot be evaluated with
standard RECIST criteria, the use of PET in response of
assessment is particularly important [12]. As is demon-
strated by Figure 2, PET is an effective tool to use in
evaluating for response in these patients.
This is the first study to evaluate the utility of PET for
assessing response following SBRT for patients with lim-
ited metastatic disease. PET has previously been evalu-
ated in patients treated with SBRT for Stage 1 non-small
cell lung cancer. Ishimori et al. studied the use of FDG-
PET in assessing the response of patients treated with
SBRT [18]. PET studies were performed 1 week before
and 1–8 weeks after treatment. Of nine patients with
imaging, two had a PET CR and seven had a PET PR.
Hoopes et al. found that in 28 patients with PET follow-
up after SBRT, 4 patients had prolonged elevation of
Figure 1 Example PET response. Coronal images of a PET scan of a patient prior to SBRT (A). Notice the hypermetabolic lesion in the liver has
had a complete response at 1 month following therapy (B), and continues to have a complete response at 19 months post-therapy (C).
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evidence of local, nodal, or distant disease [11,23].
It is interesting to note that following treatment,
residual PET activity may be present. This could indicate
a protracted inflammatory response to higher dose perFigure 2 PET response in a lesion non-measurable by CT. Pretreatmen
The black arrow points to the area of PET avidity on the pretreatment PET
what seems to be stable disease (SD) on CT, but RECIST criteria cannot be
response (CR). Pretreatment biopsy (C) and SBRT plan (F) are also depictedfraction radiotherapy. While protracted low level PET
activity has not been seen to predict for recurrence or
late toxicity, this may warrant further investigation.
It is important to acknowledge that a limitation of our
study is the relatively short median follow-up of ourt PET (A) and CT (B) of a patient with a bony metastatic lesion.
(A). PET (D) and CT (E) 1 month after completion of SBRT shows
used for bony lesions. Post treatment PET shows almost complete
.
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ally, it is difficult to make conclusions from our data
regarding the cumulative PET and CT response to SBRT
for time periods longer than our follow-up. Our results
must also be interpreted in light of the small and hetero-
geneous patient population as well as the non-
standardized follow-up PET schedule amongst our cohort.
Conclusions
PET was effective at detecting responses in oligometa-
static patients undergoing curative intent SBRT. CR by
CT correlated with PET CR. PET was able to detect
response in patients with stable disease by RECIST cri-
teria. Long-term PET response was related to radiation
dose delivered. PET scan should be part of the routine
follow-up for patients undergoing curative intent SBRT
to determine response to therapy.
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